Table 1.
Clinical, echocardiographic characteristics, DOAC administration, and procedural parameters between the minimally interrupted and uninterrupted groups
| Minimally interrupted | Uninterrupted | Total | ||
|---|---|---|---|---|
| n = 307 | n = 277 | P value | n = 584 | |
| Age, y | 65.0 ± 10.5 | 66.4 ± 10.3 | .087 | 65.7 ± 10.4 |
| Male:female | 212:95 | 211:65 | .064 | 423: 160 |
| BMI | 23.8 ± 3.4 | 24.2 ± 3.8 | .226 | 24.1 ± 3.6 |
| Type of AF | ||||
| Paroxysmal AF (n) | 199 | 171 | .513 | 370 |
| Persistent AF (n) | 61 | 65 | 126 | |
| Long‐standing persistent AF (n) | 40 | 38 | 78 | |
| Atrial tachycardia (n) | 7 | 3 | 10 | |
| AF duration (first Q:median:third Q) | 1:2:3 | 1:3:5 | <.001* | 1:2:4 |
| Hypertension n (%) | 144 (47) | 134 (48) | .740 | 278: 306 |
| Diabetes n (%) | 34 (11) | 39 (14) | .316 | 73: 556 |
| Congestive heart failure n (%) | 22 (7) | 6 (2) | .006* | 28: 556 |
| Prior stroke/TIA n (%) | 13 (4) | 16 (6) | .448 | 29: 555 |
| CHADS2 score | 0.90 ± 0.87 | 0.97 ± 0.97 | .391 | 0.93 ± 0.91 |
| CHA2DS2‐VAsc score | 1.88 ± 1.37 | 1.88 ± 1.37 | .984 | 1.88 ± 1.36 |
| HAS‐BLED score | 1.35 ± 1.05 | 1.42 ± 1.04 | .397 | 1.38 ± 1.05 |
| Left atrial diameter | 42.0 ± 6.2 | 41.8 ± 6.6 | .720 | 41.8 ± 6.5 |
| Left ventricular ejection fraction | 65.2 ± 8.0 | 65.4 ± 8.2 | .781 | 65.3 ± 8.1 |
| Antiplatelet agent n (%) | 10 (3) | 7 (3) | .632 | 17: 567 |
| DOACs | 307 | 277 | ⋯ | 584 |
| Dabigatran | 56 | 83 | .001* | 139 |
| Rivaroxaban | 109 | 65 | .002* | 174 |
| Apixaban | 59 | 58 | .607 | 117 |
| Edoxaban | 83 | 71 | .708 | 154 |
| Procedural parameters | ||||
| Procedural time, min | 98.1 ± 29.8 | 99.5 ± 31.5 | .630 | 98.6 ± 29.7 |
| Fluorescent time, min | 25.9 ± 14.0 | 26.0 ± 11.8 | .798 | 26.0 ± 13.2 |
| Application time, min | 22.8 ± 13.6 | 24.7 ± 13.3 | .116 | 23.5 ± 13.5 |
Abbreviations: AF, atrial fibrillation; BMI, body mass index; DOAC, direct oral anticoagulant; P, probability value; Q, quartile; TIA, transient ischemic attack.
*
Significant at the P < .01 level.